Pharmacokinetic properties of DOACs
| . | Direct thrombin inhibitor dabigatran . | Factor Xa inhibitor . | ||
|---|---|---|---|---|
| Rivaroxaban . | Apixaban . | Edoxaban . | ||
| Time to peak onset | 22 min-4.5 h | 1-3 h | 1-2 h | Unknown |
| Half-life | 12-14 h | 5-9 h | 8-15 h | 10-14 h |
| >24 h if CrCl is <30 mL/min | 9-13 h if patient is elderly | |||
| Drug interactions | P-gP | CYP3A4, CYP3A5, CYP2J2, P-gP | CYP3A4,P-gP | P-gP |
| Renal excretion (%) | 80 | 33 | 25 | 35 |
| . | Direct thrombin inhibitor dabigatran . | Factor Xa inhibitor . | ||
|---|---|---|---|---|
| Rivaroxaban . | Apixaban . | Edoxaban . | ||
| Time to peak onset | 22 min-4.5 h | 1-3 h | 1-2 h | Unknown |
| Half-life | 12-14 h | 5-9 h | 8-15 h | 10-14 h |
| >24 h if CrCl is <30 mL/min | 9-13 h if patient is elderly | |||
| Drug interactions | P-gP | CYP3A4, CYP3A5, CYP2J2, P-gP | CYP3A4,P-gP | P-gP |
| Renal excretion (%) | 80 | 33 | 25 | 35 |
CrCL, creatinine clearance.